Bradley L. Campbell net worth and biography

Bradley Campbell Biography and Net Worth

Bradley Campbell is the president and chief executive officer at Amicus, a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. He also serves on the company’s board of directors. He has held the president and COO roles since 2015. In 2022 he accepted the CEO position.

Campbell joined the company in 2006 as senior director of business development, and he currently directs the global commercial organization in charge of the design, strategy and execution of the Galafold™ launch. Additionally, he presides over the market access, technical operations and program management functions of the business. Before joining Amicus, he held commercial and business development positions with Genzyme and Bristol-Myers Squibb, as well as serving as business strategy consultant with Marakon Associates.

In addition to his role with Amicus, Campbell is involved with numerous boards and other charitable groups. He currently sits on the board of ARYA Sciences Acquisition Corp III, the Association for Regenerative Medicine (ARM), BioNJ and the corporate advisory board for the National Tay-Sachs and Allied Diseases Association. He previously served on the board for Progenics Pharmaceuticals.

Campbell earned his bachelor’s degree in public policy at Duke University and his M.B.A. at Harvard Business School.

What is Bradley L. Campbell's net worth?: The estimated net worth of Bradley L. Campbell is at least $8.50 million as of November 6th, 2024. Mr. Campbell owns 886,654 shares of Amicus Therapeutics stock worth more than $8,503,012 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Campbell may own. Additionally, Mr. Campbell receives an annual salary of $984,090.00 as CEO at Amicus Therapeutics. Learn More about Bradley L. Campbell's net worth.
How old is Bradley L. Campbell?: Mr. Campbell is currently 48 years old. There are 5 older executives and no younger executives at Amicus Therapeutics. Learn More on Bradley L. Campbell's age.
What is Bradley L. Campbell's salary?: As the CEO of Amicus Therapeutics, Inc., Mr. Campbell earns $984,090.00 per year. Learn More on Bradley L. Campbell's salary.
How do I contact Bradley L. Campbell?: The corporate mailing address for Mr. Campbell and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]. Learn More on Bradley L. Campbell's contact information.
Has Bradley L. Campbell been buying or selling shares of Amicus Therapeutics?: During the past quarter, Bradley L. Campbell has sold $264,212.50 in Amicus Therapeutics stock. Most recently, Bradley L. Campbell sold 7,901 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a transaction totalling $98,762.50. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at $11,083,175. Learn More on Bradley L. Campbell's trading history.
Who are Amicus Therapeutics' active insiders?: Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (CEO), Bradley Campbell (CEO), Jeff Castelli (Insider), David Clark (Insider), John Crowley (Chairman Emeritus), Margaret Mcglynn (Director), Samantha Prout (Insider), Michael Raab (Director), Ellen Rosenberg (Insider), Ellen Rosenberg (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.
Are insiders buying or selling shares of Amicus Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 25 times. They sold a total of 350,095 shares worth more than $4,532,405.15. The most recent insider tranaction occured on November, 6th when CEO Bradley L Campbell sold 7,901 shares worth more than $98,762.50. Insiders at Amicus Therapeutics own 2.2% of the company. Learn More about insider trades at Amicus Therapeutics.
Information on this page was last updated on 11/6/2024.

Bradley L. Campbell Insider Trading History at Amicus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/6/2024	Sell	7,901	$12.50	$98,762.50	886,654
11/1/2024	Sell	7,500	$11.46	$85,950.00	886,654
10/1/2024	Sell	7,500	$10.60	$79,500.00	886,654
9/3/2024	Sell	7,500	$11.71	$87,825.00	886,654
8/1/2024	Sell	7,500	$10.34	$77,550.00	886,654
7/5/2024	Sell	6,100	$10.00	$61,000.00	886,654
5/1/2024	Sell	7,500	$10.07	$75,525.00	886,654
2/15/2024	Sell	4,167	$14.00	$58,338.00	871,219
1/2/2024	Sell	15,833	$14.23	$225,303.59	947,805
12/1/2023	Sell	11,702	$11.08	$129,658.16	792,161
11/1/2023	Sell	11,700	$10.97	$128,349.00	792,161
10/2/2023	Sell	11,700	$11.24	$131,508.00	792,161
9/1/2023	Sell	18,093	$12.97	$234,666.21	792,161
8/1/2023	Sell	20,000	$13.39	$267,800.00	798,554
7/12/2023	Sell	1,500	$12.51	$18,765.00	813,654
7/3/2023	Sell	11,700	$12.31	$144,027.00	815,154
6/6/2023	Sell	8,300	$12.50	$103,750.00	815,154
6/1/2023	Sell	11,700	$11.36	$132,912.00	823,454
5/1/2023	Sell	11,700	$11.80	$138,060.00	823,454
4/3/2023	Sell	11,700	$11.21	$131,157.00	823,454
2/1/2023	Sell	20,000	$12.98	$259,600.00	845,129
1/9/2023	Sell	11,700	$11.43	$133,731.00	805,536
12/1/2022	Sell	5,485	$12.20	$66,917.00	689,618
11/1/2022	Sell	5,470	$10.01	$54,754.70	689,618
10/3/2022	Sell	5,470	$10.53	$57,599.10	689,618
8/1/2022	Sell	5,470	$10.03	$54,864.10	689,618
7/1/2022	Sell	5,470	$10.72	$58,638.40	689,618
6/21/2022	Sell	16,410	$10.00	$164,100.00	689,618
3/18/2022	Sell	10,940	$10.00	$109,400.00
1/3/2022	Sell	5,470	$11.86	$64,874.20
12/22/2021	Sell	3,000	$11.70	$35,100.00
12/1/2021	Sell	10,515	$11.00	$115,665.00
11/1/2021	Sell	10,515	$11.32	$119,029.80
10/1/2021	Sell	10,515	$10.00	$105,150.00
9/1/2021	Sell	10,515	$11.50	$120,922.50
8/5/2021	Sell	21,028	$10.02	$210,700.56
6/7/2021	Sell	10,514	$10.01	$105,245.14	436,397
5/3/2021	Sell	10,514	$10.27	$107,978.78	422,536
4/1/2021	Sell	10,514	$10.03	$105,455.42	389,371
1/4/2021	Sell	10,514	$22.17	$233,095.38	347,215
12/1/2020	Sell	24,783	$22.77	$564,308.91	363,547
11/2/2020	Sell	24,782	$17.87	$442,854.34	363,546
9/28/2020	Sell	24,782	$13.89	$344,221.98	363,546
7/8/2020	Sell	2,500	$16.01	$40,025.00	341,264
7/1/2020	Sell	12,500	$15.47	$193,375.00	351,264
6/1/2020	Sell	17,502	$12.66	$221,575.32	365,355
5/26/2020	Sell	2,500	$13.01	$32,525.00	357,855
5/1/2020	Sell	17,503	$11.33	$198,308.99	372,858
4/7/2020	Sell	2,500	$10.12	$25,300.00	365,358
4/1/2020	Sell	15,003	$9.09	$136,377.27	363,014
3/5/2020	Sell	2,500	$10.01	$25,025.00	358,014
2/5/2020	Sell	2,500	$10.01	$25,025.00	365,517
2/3/2020	Sell	15,003	$8.91	$133,676.73	378,020
1/15/2020	Sell	5,064	$10.35	$52,412.40	370,520
1/9/2020	Sell	2,500	$10.01	$25,025.00	347,695
1/2/2020	Sell	22,127	$9.58	$211,976.66	253,987
1/22/2019	Sell	36,000	$11.81	$425,160.00	275,360
1/22/2018	Sell	32,500	$15.92	$517,400.00	186,600
3/2/2017	Sell	49,050	$8.00	$392,400.00	127,475
9/21/2015	Sell	13,001	$16.78	$218,156.78	156,575
6/19/2015	Sell	13,000	$13.26	$172,380.00
11/25/2014	Sell	7,250	$8.00	$58,000.00
8/25/2014	Sell	7,000	$6.00	$42,000.00
8/20/2014	Sell	18,750	$5.40	$101,250.00

Bradley L. Campbell Buying and Selling Activity at Amicus Therapeutics

Amicus Therapeutics Company Overview

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $9.59

$9.38

$9.68

50 Day Range

MA: $10.89

$9.52

$12.01

2 Week Range

Now: $9.59

$9.02

$14.57

Volume

1,961,452 shs

Average Volume

2,723,220 shs

Market Capitalization

$2.87 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>

Bradley Campbell Biography and Net Worth

What is Bradley L. Campbell's net worth?

How old is Bradley L. Campbell?

What is Bradley L. Campbell's salary?

How do I contact Bradley L. Campbell?

Has Bradley L. Campbell been buying or selling shares of Amicus Therapeutics?

Who are Amicus Therapeutics' active insiders?

Are insiders buying or selling shares of Amicus Therapeutics?